既往卒中合并糖尿病急性缺血性卒中患者静脉rt-PA治疗的安全性
结果显示两组症状性颅内出血和院内死亡率无统计学显著差异,但既往卒中合并糖尿病者出院时功能独立率更低。
要点
- 既往卒中合并糖尿病不显著增加症状性颅内出血风险(aOR 0.79,95%CI 0.51-1.21)。
- 院内死亡率两组无显著差异(aOR 0.77,95%CI 0.52-1.14)。
- 既往卒中合并糖尿病者出院功能独立率更低(aOR 0.76,95%CI 0.59-0.99)。
核心结论
- 在3-4.5小时窗内接受静脉rt-PA治疗的急性缺血性卒中患者中,既往卒中合并糖尿病与症状性颅内出血或院内死亡风险无显著增加相关。
- 但既往卒中合并糖尿病者出院时功能独立率显著低于无二者病史者。
研究设计与样本
- 基于 get with the guidelines-stroke 注册研究(2009年2月至2017年9月,1619家医院)的回顾性队列分析。
主要发现
- 既往卒中合并糖尿病组症状性颅内出血未调整率为4.3%,无二者病史组为3.8%(P=0.31)。
- 既往卒中合并糖尿病组院内死亡未调整率为6.2%,无二者病史组为5.5%(P=0.20)。
- 风险调整后症状性颅内出血aOR 0.79(95%CI 0.51-1.21,P=0.28),院内死亡aOR 0.77(95%CI 0.52-1.14,P=0.19)。
- 出院时功能独立(mRS 0-2)未调整率:既往卒中合并糖尿病组30.9%,无二者病史组44.8%(P≤0.0001)。
- 调整基线临床因素后功能独立aOR 0.76(95%CI 0.59-0.99,P=0.04)。
关键数值与推荐
- 症状性颅内出血风险调整后aOR 0.79(95%CI 0.51-1.21),P=0.28。
- 院内死亡风险调整后aOR 0.77(95%CI 0.52-1.14),P=0.19。
- 功能独立(mRS 0-2)调整后aOR 0.76(95%CI 0.59-0.99),P=0.04。
临床怎么用
- 对于3-4.5小时窗内急性缺血性卒中且既往卒中合并糖尿病的患者,静脉rt-PA不因安全性顾虑而排除。
- 此类患者功能预后较差,治疗决策需结合个体风险获益评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Acute ischemic stroke patients with history of prior ischemic stroke plus concomitant diabetes mellitus (DM) were excluded from the ECASS III trial (European Cooperative Acute Stroke Study) because of safety concerns. However, there are few data on use of intravenous tissue-type plasminogen activator and symptomatic intracerebral hemorrhage or outcomes in this population. Methods- Using data from the Get With The Guidelines-Stroke Registry between February 2009 and September 2017 (n=1619 hospitals), we examined characteristics and outcomes among patients with acute ischemic stroke treated with tissue-type plasminogen activator within the 3- to 4.5-hour window who had a history of stroke plus diabetes mellitus (HxS+DM) (n=2129) versus those without either history (n=16 690). Results- Compared with patients without either history, those with both prior stroke and DM treated with tissue-type plasminogen activator after an acute ischemic stroke had a higher prevalence of cardiovascular risk factors in addition to history of stroke, DM, and more severe stroke (National Institutes of Health Stroke Scale: median, 8 [interquartile range, 5-15] versus 7 [4-13]). The unadjusted rates of symptomatic intracerebral hemorrhage and in-hospital mortality were 4.3% (HxS+DM) versus 3.8% (without either history; P=0.31) and 6.2% versus 5.5% ( P=0.20), respectively. These differences were not statistically significant after risk adjustment (symptomatic intracerebral hemorrhage: adjusted odds ratio, 0.79 [95% CI, 0.51-1.21]; P=0.28; in-hospital mortality: odds ratio, 0.77 [95% CI, 0.52-1.14]; P=0.19). Unadjusted rate of functional independence (modified Rankin Scale score, 0-2) at discharge was lower in those with HxS+DM (30.9% HxS+DM versus 44.8% without either history; P≤0.0001), and this difference persisted after adjusting for baseline clinical factors (adjusted odds ratio, 0.76 [95% CI, 0.59-0.99]; P=0.04). Conclusions- Among patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator within the 3- to 4.5-hour window, HxS+DM was not associated with statistically significant increased symptomatic intracerebral hemorrhage or mortality risk.
引用
- Ehrlich ME, Liang L, Xu H, et al. Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus. Stroke. 2019. PMID: 31035901. doi:10.1161/STROKEAHA.118.024172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。